Tharimmune announces dosing of first patient in phase 1 clinical trial of th104, its lead candidate for pruritus in primary biliary cholangitis

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of th104 phase 1 study expected to be completed in 1q24 with topline readout in 2q24 company fully funded into 2025 with full readouts of phase 1 and 2 in moderate-to-severe chronic pruritus in pbc expected in 4q24/1q25 bridgewater, nj / accesswire / february 5, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the first patient dosed in the company's phase 1 clinical trial with th104, utilizing a proprietary oral thin film. th104 is a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene onto a thin film which easily adheres inside of the mouth on the cheek and biodegrades within minutes.
THAR Ratings Summary
THAR Quant Ranking